No connection

Search Results

ABBV vs ARCT

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ARCT
--
Forward P/E
ABBV
15.42
ARCT
-1.61
P/B Ratio
ABBV
-146.66
ARCT
0.89
P/S Ratio
ABBV
6.5
ARCT
2.31
EV/EBITDA
ABBV
15.27
ARCT
0.22

Profitability

Gross Margin
ABBV
71.46%
ARCT
-36.79%
Operating Margin
ABBV
35.5%
ARCT
-435.06%
Profit Margin
ABBV
4.0%
ARCT
-80.19%
ROE
ABBV
137.96%
ARCT
-28.92%
ROA
ABBV
9.59%
ARCT
-15.5%

Growth

Revenue Growth
ABBV
9.1%
ARCT
-68.4%
Earnings Growth
ABBV
-88.7%
ARCT
--

Financial Health

Debt/Equity
ABBV
--
ARCT
0.12
Current Ratio
ABBV
0.72
ARCT
6.64
Quick Ratio
ABBV
0.47
ARCT
6.5

Dividends

Dividend Yield
ABBV
3.05%
ARCT
--
Payout Ratio
ABBV
490.15%
ARCT
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)

Compare Another Pair

ABBV vs ARCT: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Arcturus Therapeutics Holdings Inc. (ARCT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile